Based on validated drug targets in JAK-STAT/Th-GM pathway, the Company is developing precision medicine focusing on autoimmune diseases and cancer.
Rheumatoid arthritis is a systemic autoimmune disease that affects multiple organs and tissues, including joints, significantly impairs quality of life and increases the risk of death. It affects 0.5% to 1% of adults, or 5 to 50 per 100,000 people per year in developed countries. China has more than 5 million people suffering from rheumatoid arthritis. About 49,000 people died from the disease in 2010, resulting in a medical burden of more than $100 billion a year in Europe and the United States.
» The JAK-STAT cell signaling pathways first discovered by Professor Fu Xin-Yuan (Cell, 1992) has been proven to be a safe and effective drug targets.
» Over the past two decades, more than 40,000 papers on JAK-STAT have been published, 5 drugs have received FDA approvals, and reported sales of the drugs were approximately $6 billion in 2018.
» The discovery of STAT was rated as one of the top ten major scientific achievements by Science magazine in 1993.
The JAK-STAT signaling pathway is unique in that STAT is both a signal transducer and a transcriptional activator, which plays a key role in cytokine signaling.
Different members of the STAT family proteins have different roles in fundamental. cell activities such as cell division, programmed cell death, and cell differentiation.
STATs have important functions in immune cell differentiation, inflammation, neural differentiation, cancer and many other important biological processes.
STAT1, 3, and 5 are particularly important for immune and inflammation-related diseases.
Professor Fu Xin-Yuan's team discovered a new inflammatory mechanism in 2014, and found a new drug target point for the pathway!
Preliminary evidences suggested that the Th-GM theory has created a huge market of drugs for patients who do not respond to the TNFα therapy, filling a gap in the field of autoimmune diseases.